Skip to main content
SpringerLink
Log in

Switching epoetin alfa and epoetin zeta in patients with Renal Anemia on Dialysis: Posthoc analysis

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Epoetin zeta is a recently introduced recombinant erythropoietin, designed to be biologically similar to epoetin alfa. This posthoc analysis evaluated the impact of switching patients with chronic kidney disease (CKD) on hemodialysis from epoetin alfa to epoetin zeta, or vice versa, on hemoglobin concentration, epoetin dose, and patient safety.

Methods

Data were analyzed from three published trials: two 24-week randomized, double-blind (maintenance and induction) studies and a 56-week, open-label, follow-on study involving adult patients with CKD stage 5, maintained on hemodialysis, and receiving epoetin alfa or epoetin zeta. Patients had either completed and switched treatments within the maintenance study, or had completed the induction or maintenance study on epoetin alfa and then switched to, and completed at least 12 weeks of follow-up treatment on, epoetin zeta. Mean hemoglobin levels and epoetin dose were evaluated pre- (0–4 weeks before) and post- (8–12 weeks after) switch, and were considered equivalent for the two treatments if the upper and lower limits of the 95% confidence intervals (CIs) for the intraindividual differences in mean values fell within accepted limits.

Results

Overall, 481 patients were included in the analysis. Mean hemoglobin concentration was maintained at target levels (10.5–12.5 g/dL) throughout the drug switch. The mean differences in hemoglobin concentration and associated 95% CIs following the switch remained within prespecified equivalence limits (±1.0 g/dL). The 95% CIs of the mean difference in weekly epoetin dose postswitch also remained within prespecified equivalence margins (±45 IU/kg; upper limit 17.83 IU/kg, lower limit −10.91 IU/kg). Both treatments were similarly well tolerated.

Conclusion

Our data suggest that epoetin alfa and epoetin zeta therapy can be interchanged without any clinically significant alteration in efficacy, safety, or epoetin dose, in patients with CKD on dialysis receiving stable epoetin maintenance therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990;300:573–578.

    Article  Google Scholar 

  2. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992–1000.

    CAS  PubMed  Google Scholar 

  3. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353–361.

    Article  CAS  PubMed  Google Scholar 

  4. Raftery MJ, Auinger M, Hertlova M. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Collaborative Study Group. Clin Nephrol. 2000;54:240–245.

    CAS  PubMed  Google Scholar 

  5. Ritz E, Eisenhardt A. Early epoetin treatment in patients with renal insufficiency. Nephrol Dial Transplant. 2000;15(Suppl. 3):40–44.

    Google Scholar 

  6. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther. 2003;25:1786–1805.

    Article  PubMed  Google Scholar 

  7. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S11–145.

    Google Scholar 

  8. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471–530.

    Google Scholar 

  9. National Institute for Health and Clinical Excellence. Clinical Guidelines CG39. Anaemia management in chronic kidney disease. Available at http://guidance.nice.org.uk/CG39. Accessed August 18, 2010.

  10. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl. 2):ii1–47.

    Article  PubMed  Google Scholar 

  11. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24:348–354.

    Article  PubMed  Google Scholar 

  12. Barbone FP, Johnson DL, Farrell FX, et al. New epoetin molecules and novel therapeutic approaches. Nephrol Dial Transplant. 1999;14(Suppl. 2):80–84.

    Article  CAS  PubMed  Google Scholar 

  13. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008;36:1573–1584.

    Article  CAS  PubMed  Google Scholar 

  14. Jelkmann W. Molecular biology of erythropoietin. Intern Med. 2004;43:649–659.

    Article  CAS  PubMed  Google Scholar 

  15. European Generic Medicines Association. Biosimilar medicines FAQ. Available at http://198.170.119.137/FAQ-biosimilars.htm. Accessed August 18, 2010.

  16. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411–419.

    Article  CAS  PubMed  Google Scholar 

  17. Schellekens H. Biosimilar therapeutics - what do we need to consider? NDT Plus. 2009;2:i27–i36.

    Article  CAS  PubMed  Google Scholar 

  18. European Medicines Agency. Retacrit European Public Assessment Report. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000872/human_med_001031.sjsp&murl=menus/medicines/medicines.jsp&jsenabled=true. Accessed August 18, 2010.

  19. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Annex to guidelines on similar biological medicinal products containing biotechnologyderived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant erythropoietins. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003921.pdf. Accessed August 18, 2010.

  20. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf. Accessed August 18, 2010.

  21. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf. Accessed August 18, 2010.

  22. Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Weigel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008;25:1215–1228.

    Article  CAS  PubMed  Google Scholar 

  23. Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin. 2008;24:1407–1415.

    Article  CAS  PubMed  Google Scholar 

  24. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24:625–637.

    Article  CAS  PubMed  Google Scholar 

  25. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant. 2006;21(Suppl. 5):v9–12.

    Article  CAS  PubMed  Google Scholar 

  26. Covic A, Cannata-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know - a position paper by the ERA-EDTA Council. Nephrol Dial Transplant. 2008;23:3731–3737.

    Article  PubMed  Google Scholar 

  27. Declerck PJ. Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf. 2007;30:1087–1092.

    Article  PubMed  Google Scholar 

  28. Kramer I. Pharmacy and pharmacology of biosimilars. J Endocrinol Invest. 2008;31:479–488.

    CAS  PubMed  Google Scholar 

  29. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res. 2007;30:267–272.

    Article  PubMed  Google Scholar 

  30. Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005;25:954–962.

    Article  CAS  PubMed  Google Scholar 

  31. Deechongkit S, Aoki KH, Park SS, Kerwin BA. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci. 2006;95:1931–1943.

    Article  CAS  PubMed  Google Scholar 

  32. Park SS, Park J, Ko J, et al. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci. 2009;98:1688–1699.

    Article  CAS  PubMed  Google Scholar 

  33. Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm. 2004;3:43–47.

    Google Scholar 

  34. Zuniga L, Calvo B. Regulatory aspects of biosimilars in Europe. Trends Biotechnol. 2009;27:385–387.

    Article  CAS  PubMed  Google Scholar 

  35. European Directorate for the Quality of Medicines. The European Pharmacopoeia. 6th edition. Strasbourg, Paris; July 16, 2007. Available at: http://online6.edqm.eu/ep608/. Accessed August 18, 2010.

Download references

Author information

Authors and Affiliations

  1. Internal Medicine and Nephrology, and Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Silesia, Francuska 20-24 Str, PL-40-027, Katowice, Poland

    Andrzej Więcek

  2. Global Medical Affairs, Hospira Inc., Lake Forest, IL, USA

    Islah Ahmed

  3. Pharmaceutical Research Consulting Berlin, Kladower Damm 37J, D - 14089, Berlin, Germany

    Paul Scigalla

  4. CCDRD AG, Fontanestraße 84-90, 15366, Neuenhagen, Germany

    Rossen Koytchev

Authors
  1. Andrzej Więcek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Islah Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Scigalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rossen Koytchev
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rossen Koytchev.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Więcek, A., Ahmed, I., Scigalla, P. et al. Switching epoetin alfa and epoetin zeta in patients with Renal Anemia on Dialysis: Posthoc analysis. Adv Therapy 27, 941–952 (2010). https://doi.org/10.1007/s12325-010-0080-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0080-z

Keywords

Search

Navigation